Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  11:13 2022-12-06 am EST
0.6360 EUR   -0.31%
11/29MDxHealth Provides Business Update
GL
11/29MDxHealth Provides Business Update
GL
11/29MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MDxHealth Announces its Ordinary and Extraordinary General Shareholders' Meetings

04/25/2022 | 04:00pm EST

           NEWS RELEASE - REGULATED INFORMATION
                25 April 2022, 10:00 p.m. CET

MDxHealth Announces its Ordinary and Extraordinary
General Shareholders’ Meetings

IRVINE, CA, and HERSTAL, BELGIUM25 April 2022MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its ordinary and extraordinary general shareholders' meetings that will be held on Wednesday, 25 May 2022 at 10:00 a.m., Belgian time.

The items on the agenda of the ordinary and extraordinary general shareholders' meetings include the proposed approval of a number of resolutions relating to the financial year ended on 31 December 2021, as well as the issuance of a new share option plan called the "2022 Share Option Plan".

In light of the COVID-19 pandemic and the measures possibly imposed by the Belgian government to deal with this pandemic, which may (still) be in effect on Wednesday 25 May 2022 (i.e., the scheduled date of the shareholders' meetings of the Company), the board of directors recommends holders of securities issued by the Company that wish to participate to the general shareholders' meetings make use, as much as practically possible, of the right to vote through voting by mail or by means of a written proxy to the chair of the board of directors.

In order to participate to the ordinary and extraordinary general shareholders’ meetings of the Company, the holders of securities issued by the Company must comply with Article 7:134, §2, first indent of the Belgian Companies and Associations Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice, forms and other documents relating to the ordinary and extraordinary general shareholders’ meetings can be consulted on the Company’s website.

The Company recommends holders of its securities to use e-mail for all communication with the Company regarding the general shareholders' meetings. The Company's email address for such communication is: agsm@mdxhealth.com.

About MDxHealth®

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

MDxHealth

info@mdxhealth.com

 

Important information
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA ("MDxHealth"). All other trademarks and service marks are the property of their respective owners.

 

 

 

Attachment

  • PR English

© OMX, source GlobeNewswire - EU Press Releases

All news about MDXHEALTH SA
11/29MDxHealth Provides Business Update
GL
11/29MDxHealth Provides Business Update
GL
11/29MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023
CI
11/29MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022
CI
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
10/27MDxHealth SA Reaffirms Revenue Guidance for the Year 2022
CI
10/27MDxHealth SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
More news
Analyst Recommendations on MDXHEALTH SA
More recommendations
Financials
Sales 2022 35,5 M 37,4 M 37,4 M
Net income 2022 -33,5 M -35,3 M -35,3 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 104 M 109 M 109 M
Capi. / Sales 2022 2,92x
Capi. / Sales 2023 1,70x
Nbr of Employees 191
Free-Float 84,3%
Chart MDXHEALTH SA
Duration : Period :
MDxHealth SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH SA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,64
Average target price
Spread / Average Target -
Managers and Directors
Michael K. McGarrity Chief Executive Officer & Executive Director
Ron Kalfus Chief Financial Officer
Koen Hoffman Chairman
Miriam Reyes Executive Vice President-Operations
Joseph Sollee Chief Compliance Officer, EVP & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MDXHEALTH SA-27.89%109
MODERNA, INC.-30.73%70 055
IQVIA HOLDINGS INC.-24.88%40 441
LONZA GROUP AG-34.60%39 280
ALNYLAM PHARMACEUTICALS, INC.33.39%28 838
SEAGEN INC.-23.73%22 727